Wysolone

# Wysolone ## Overview - **Classification**: Corticosteroid, Glucocorticoid - **Mechanism**: Potent anti-inflammatory and immunosuppressant. Binds to intracellular glucocorticoid receptors, modulating gene expression. ## Primary Indications 1. **Anti-inflammatory/Immunosuppressive**: Allergic conditions, dermatologic, ophthalmic, respiratory, rheumatic, hematologic, and neoplastic diseases. 2. **Endocrine Disorders**: Primary or secondary adrenocortical insufficiency (often used with mineralocorticoids). 3. **Specific Conditions**: Multiple sclerosis exacerbations, nephrotic syndrome, inflammatory bowel disease. ## Adult Dosing ### Standard Dosing **Anti-inflammatory/Immunosuppressive** (highly variable, individualized) - **Dose**: **5 mg** to **60 mg** - **Frequency**: Once daily or divided doses - **Route**: Oral - **Duration**: Acute treatment is often short-term; chronic diseases require maintenance. **Multiple Sclerosis Exacerbations** - **Dose**: **200 mg** - **Frequency**: Once daily - **Route**: Oral - **Duration**: For 7 days, followed by **80 mg** every other day for 1 month. **Nephrotic Syndrome** - **Dose**: **60 mg** or **2 mg/kg** (max **80 mg**) - **Frequency**: Once daily or divided - **Route**: Oral - **Duration**: Up to 6 weeks, then taper. ### Dose Adjustments - **Renal Impairment**: No specific dose adjustment generally needed as primarily hepatic metabolism. - **Hepatic Impairment**: Use caution. Reduced clearance may occur; consider lower initial doses. Monitor for increased side effects. - **Elderly Patients**: Use with caution due to increased risk of osteoporosis, hyperglycemia, and fluid retention. Start with lower doses. ## Pediatric Dosing ### Neonates (0-28 days) - Use with extreme caution; generally avoided due to growth suppression risks. - **Dose**: Individualized by specialist, e.g., for bronchopulmonary dysplasia, **0.5-2 mg/kg/day**. - **Frequency**: Once daily or divided BID/TID. - **Maximum**: Highly variable, depends on indication. - **Special Notes**: Monitor closely for adrenal suppression, hyperglycemia, hypertension, and growth. ### Infants (1-12 months) - **Anti-inflammatory/Immunosuppressive**: **0.1-2 mg/kg/day** - **Frequency**: Once daily or divided BID/TID. - **Maximum**: Do not exceed adult maximum for specific indications. - **Special Notes**: Critical to monitor growth and development. Taper slowly if prolonged use. ### Children (1-12 years) - **Anti-inflammatory/Immunosuppressive**: **0.1-2 mg/kg/day** - **Frequency**: Once daily or divided BID/TID. - **Maximum**: Up to **60 mg/day** for maintenance, or higher for acute pulse therapy (e.g., **2 mg/kg/day** up to **60-80 mg/day** for nephrotic syndrome). - **Special Notes**: Alternate-day therapy may reduce growth suppression for chronic conditions. ### Adolescents (13-18 years) - **Dose**: Generally follows adult dosing guidelines. - **Maximum**: Adult maximum dose. - **Special Notes**: Consider growth plate status if long-term use is anticipated. ## Safety Information ### Contraindications - **Absolute**: Systemic fungal infections (unless used with anti-fungals). - **Absolute**: Hypersensitivity to prednisolone or any component. - **Relative**: Live or live-attenuated vaccines during immunosuppressive doses. ### Common Adverse Effects (Dose and duration dependent) - **Very Common (>10%)**: Fluid retention, increased appetite, weight gain, insomnia, mood changes. - **Common (1-10%)**: Hyperglycemia, hypertension, dyspepsia, muscle weakness, skin thinning, acne. - **Serious but Rare**: Adrenal suppression, osteoporosis, avascular necrosis, cataracts, glaucoma, GI ulceration, opportunistic infections, acute pancreatitis. ### Key Drug Interactions - **CYP3A4 Inducers (e.g., Rifampin, Phenytoin, Phenobarbital)**: May decrease prednisolone levels; consider dose increase. - **CYP3A4 Inhibitors (e.g., Ketoconazole, Ritonavir)**: May increase prednisolone levels; consider dose reduction. - **NSAIDs**: Increased risk of GI ulceration/bleeding. Use with caution. - **Warfarin**: Can alter anticoagulant effects (increase or decrease). Monitor INR closely. - **Diuretics (Thiazide, Loop)**: May enhance potassium wasting, leading to hypokalemia. ## Monitoring & Follow-up - **Before Treatment**: Baseline weight, blood pressure, electrolytes, blood glucose, ocular exam (for long-term use). - **During Treatment**: Monitor BP, weight, blood glucose (especially in diabetics), electrolytes, signs of infection. - **Clinical Signs**: Watch for fluid retention, mood changes, muscle weakness, bruising, vision changes. ## Clinical Pearls - 💡 **Tip 1**: Administer with food or milk to minimize GI upset. - 💡 **Tip 2**: For chronic conditions, alternate-day therapy may reduce adrenal suppression and other side effects. - 💡 **Tip 3**: Taper slowly after prolonged therapy to prevent adrenal crisis. Do not stop abruptly. - 💡 **Tip 4**: Patients on corticosteroids are at increased risk of infection; counsel on symptom recognition. - 💡 **Tip 5**: Long-term use requires calcium and vitamin D supplementation to prevent osteoporosis. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.